Best Cash-Pay GLP-1 Telehealth Platforms in 2026

If your insurance does not cover GLP-1s for obesity — and many plans do not — cash-pay is the path. The options in 2026 split into two tracks: compounded semaglutide or tirzepatide from a §503A telehealth platform, or branded GLP-1 direct from the manufacturer at published flat rates.

This page maps the real costs and trade-offs, so you can match the right option to your priorities.

Quick reference: cash-pay prices at a glance (May 2026)

All prices current as of May 2026. Verify at the provider's site before enrolling — these are the fields most likely to change.

The two tracks and what separates them

Track 1: Compounded §503A

Compounded semaglutide and tirzepatide are prepared by licensed 503A compounding pharmacies under a prescriber's patient-specific order. They are lower cost because they are not manufactured as finished, FDA-approved drug products. The active ingredient is the same molecule; quality control and lot testing standards vary by pharmacy.

The legal framework: §503A(b)(1)(D) of the Federal Food, Drug, and Cosmetic Act allows compounding when a drug is "essentially a copy" of an approved drug but includes a "clinical difference" the prescriber has documented for a specific patient. As of May 2026, this is the only active compounding pathway for GLP-1s — the 503B bulk-substances pathway closed on May 22, 2025.

What this means practically: compounded GLP-1 providers that are still operating are legal. But the legal basis is contested, and brand-manufacturer patent litigation (Novo Nordisk's active suit against Mochi, Fella, and others; Eli Lilly's suit against Mochi) adds provider-specific risk on top of the regulatory landscape. Hims exited the compounding market via a settlement with Novo Nordisk in March 2026.

For the current legal status of each provider, the compounding tracker is updated weekly.

Track 2: Branded manufacturer direct

NovoCare (Wegovy) and LillyDirect (Zepbound) are direct-from-manufacturer programmes that sell the FDA-approved branded products at published flat rates. You need a valid prescription — which a telehealth provider or your own prescriber can issue. The drug ships directly; no need for a separate pharmacy visit.

The trade-off: higher monthly cost, but zero regulatory-continuity risk. The branded drugs are not going away. The same clinical trial data on the label — STEP trials for Wegovy, SURMOUNT for Zepbound — applies to the pill you are taking.

For patients who can absorb $349–449/month, branded direct is the simpler, lower-uncertainty path.

Compounded cash-pay options in detail

Eden — best for lowest sticker price

Eden charges $229/month for compounded semaglutide and $329/month for tirzepatide at all dose levels. No membership fee. No dose-based surcharge. The first month is discounted ($149 for sema, $249 for tirze).

Eden has not received an FDA warning letter as of May 2026. The Novo Nordisk patent suit named Mochi and Fella specifically; Eden has not been named in the public litigation record. That is meaningful, but not a guarantee.

Who it is right for: patients who want the lowest cash-pay price with minimal platform overhead and no per-platform fee. Full review: Eden Health review.

Mochi Health — best flat-rate with PA support

Mochi's compounded medication prices ($99/mo for sema, $199/mo for tirze) are the lowest on the market before the membership fee. With the $79/month membership, true costs are $178/mo (sema) and $278/mo (tirze) — still below most alternatives at higher doses where dose surcharges apply at other providers.

The distinctive feature: Mochi also provides active prior-authorisation support for commercial insurance. If you have insurance that might cover Wegovy or Zepbound, Mochi will work the PA process while you pay cash-pay rates during the wait. If PA succeeds, you transition to branded drug at your copay; if it doesn't, you stay on compounded. That optionality has value.

Material risks: Eli Lilly's lawsuit against Mochi survived a motion to dismiss in April 2026 and is proceeding. Washington State suspended Mochi's original pharmacy partner (Aequita) in March 2025 for sterile compounding violations; Mochi uses alternate pharmacies now. Neither has shut down Mochi's programme.

Full review: Mochi Health review.

Henry Meds — best for all-in pricing clarity

Henry Meds bundles the prescriber relationship and medication into one published price with no separate platform fee. Semaglutide: $297/month at standard dose (up to 1 mg), $397/month above standard. Tirzepatide: $449/month. No membership add-on; what you see is what you pay.

The surcharge above the 1 mg semaglutide dose is the main cost variable to watch. Patients who reach a 1.5–2 mg maintenance dose pay roughly $100/month more than the headline price. At those doses, Henry Meds' compounded option exceeds NovoCare's branded Wegovy price.

No FDA warning letter as of May 2026. Full review: Henry Meds review.

Fella — best for men who want coaching included

Fella is men-only. Pricing ranges from roughly $165/month (12-month prepaid) to $299/month (monthly plan) for semaglutide, and $399–449/month for tirzepatide. All-inclusive: medication, bi-weekly coaching, and lab work. An active federal trademark suit filed by Novo Nordisk in August 2025 (N.D. Cal.) was still pending as of latest docket update.

Worth it if the male-specific coaching model and community are valued features. Not the right choice if price minimisation is the primary goal. Full review: Fella Health review.

Branded manufacturer direct in detail

NovoCare (branded Wegovy)

$349/month flat for all dose tiers, including the high-dose Wegovy HD (7.2 mg, approved March 2026). Introductory rate: $199/month for the two lowest doses (0.25 mg and 0.5 mg). No insurance required. Prescription required — obtain from your own prescriber or a telehealth provider.

NovoCare is Novo Nordisk's direct-to-patient programme. It covers Wegovy (semaglutide for weight management) and does not cover Ozempic (semaglutide for T2D). If your prescriber writes for Ozempic off-label for weight loss, NovoCare pricing does not apply.

LillyDirect (branded Zepbound)

Dose-tier pricing: $299/month for 2.5 mg and 5 mg; $399/month for 7.5 mg and 10 mg; $449/month for 12.5 mg and 15 mg. Available as vials or KwikPen at the same price since February 2026. Vials typically offer more injection-volume flexibility for some patients. Prescription required.

For the complete enrolment process for LillyDirect, see the LillyDirect Zepbound enrollment guide.

When branded direct is worth the premium

At $229/month for Eden compounded semaglutide versus $349/month for branded Wegovy, the gap is $120/month — $1,440/year. Whether that premium is worth paying depends on:

Regulatory continuity horizon: On a 12–24 month treatment plan, branded eliminates the risk of your provider winding down mid-treatment. Compounded providers can and do exit the market — Hims did in March 2026.

Clinical trial data: Branded Wegovy carries the STEP trial results on its label. Compounded semaglutide is the same molecule, but there are no Phase 3 trials of the specific compounded formulations.

Dose flexibility: Wegovy HD (7.2 mg) is available via NovoCare. Compounded providers offering equivalent dose flexibility will vary. If your prescriber determines you need doses above 2.4 mg, the branded route is the straightforward path.

Insurance compatibility: Some patients with insurance that partially covers GLP-1s (e.g. after a deductible, or with a high copay) find that branded drugs interact better with their plan than compounded medications, which are typically not covered and cannot be submitted for reimbursement.

For a comparison of the full provider landscape — including insurance-navigating platforms — see GLP-1 telehealth provider comparison.